Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1200 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Sodium thiosulfate for acute calciphylaxis-associated pain in chronic haemodialysis patients	Sodium Thiosulfate (Pedmark; BYON5667)	Calciphylaxis	Cardiovascular System	2018	View \| Download
Somapacitan for treating idiopathic short stature or Noonan syndrome or small for gestational age in people aged 2 to 18 years	Somapacitan (NNC0195-0092; NN-8640)	Idiopathic short stature or Noonan syndrome or Small for gestational age	Endocrine Nutritional and Metabolic Disorders , Genetic Disorders	2024	View \| Download
Sotagliflozin for type 2 diabetes mellitus	Sotagliflozin (Zynquista; SAR439954; LX4211)	Type 2 diabetes	Endocrine Nutritional and Metabolic Disorders	2019	View \| Download
Sotagliflozin tablets as an adjuct therapy to insulin for Type 1 diabetes mellitus	Sotagliflozin (Zynquista; SAR439954; LX4211)	Type 1 diabetes	Endocrine Nutritional and Metabolic Disorders	2017	View \| Download
Sotatercept for treating pulmonary arterial hypertension	Sotatercep (ACE-011)	Pulmonary arterial hypertension (PAH)	Cardiovascular System , Respiratory System	2022	View \| Download
Soticlestat as an adjunctive therapy for treatment of Lennox-Gastaut syndrome	Soticlestat	Lennox-Gastaut syndrome	Neurology	2024	View \| Download
Soticlestat as an adjunctive therapy in patients with Dravet syndrome	Soticlestat	Dravet syndrome	Neurology	2024	View \| Download
Sparsentan for treating Focal Segmental Glomerulosclerosis	Sparsentan (RE-021; PS433540)	Focal segmental glomerulosclerosis (FSGS)	Nephrology	2021	View \| Download
Sparsentan for treating primary IgA nephropathy	Sparsentan (RE-021; PS433540)	IgA nephropathy	Immunology , Nephrology	2023	View \| Download
Spartalizumab in addition to dabrafenib and trametinib for unresectable or metastatic BRAF V600 mutant melanoma – first‐line	Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Spartalizumab (PDR001) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide)	Melanoma	Skin Cancer	2019	View \| Download